bioAffinity Technologies, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $7.2M
- Price
- $6.16
- % Change (Daily % change from the live per-ticker quote feed.)
- +1.65%
- Volume
- 87.7K
About
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.
Quick stats
Shares outstanding1.2M
Computed float1.1M
Float / shares92.5%
Cash runway (months)2.3
Key info
SectorHealthcare
IndustryMedical - Diagnostics & Research
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001712762
AI Summary
AI-generated1/50
standardbullishoperations update
bioAffinity Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026
bioAffinity Technologies reported that CyPath Lung sales rose more than 100% through Q3 2026 versus the prior year, with tests delivered climbing to over 1,620 from 775 through Q3 2025.
The number of ordering physicians grew 89% year-over-year, while physicians who adopted the test in 2025 increased their utilization by 48%, pointing to both new adoption and deepening repeat usage.
Management highlighted a new distribution agreement with Veteran-Owned AvMEDICAL aimed at broadening reach in the government healthcare system, including the Department of Veterans Affairs.
Red flags
- sales growth disclosed without revenue dollars, making absolute commercial scale hard to assess
- company notes need for additional capital in forward-looking statements
- CyPath Lung is an LDT subject to evolving FDA regulatory requirements for laboratory developed tests